Evoke Pharma, Inc. (EVOK) Revenue History
Annual and quarterly revenue from 2011 to present
EVOK Revenue Over Time (2011–2024)
EVOK Revenue Growth History
4 of 4 years with positive growth- FY2011 revenue growth
- N/A
- FY2012 revenue growth
- N/A
- FY2013 revenue growth
- N/A
- FY2014 revenue growth
- N/A
- FY2015 revenue growth
- N/A
- FY2016 revenue growth
- N/A
- FY2017 revenue growth
- N/A
- FY2018 revenue growth
- N/A
- FY2019 revenue growth
- N/A
- FY2020 revenue growth
- N/A
- FY2021 revenue growth
- +6929.0%
- FY2022 revenue growth
- +55.0%
- FY2023 revenue growth
- +106.5%
- FY2024 revenue growth
- +97.8%
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2025 | $4.3M | +61.4% |
| Q2 2025 | $3.8M | +47.1% |
| Q1 2025 | $3.1M | +77.5% |
| Q4 2024 | $3.3M | +97.4% |
| Q3 2024 | $2.7M | +69.8% |
| Q2 2024 | $2.6M | +125.5% |
| Q1 2024 | $1.7M | +114.2% |
| Q4 2023 | $1.7M | +110.5% |
Multi-year avg. share of annual revenue by fiscal quarter
Revenue Breakdown (FY 2024)
EVOK's revenue distribution by segment and geography for fiscal year 2024
By Product/Segment
EVOK Revenue Analysis (2011–2024)
Current Revenue & Growth
As of June 29, 2026, Evoke Pharma, Inc. (EVOK) generated trailing twelve-month (TTM) revenue of $14.4 million, reflecting explosive growth of +61.4% year-over-year. The most recent quarter (Q3 2025) recorded $4.3 million in revenue, up 14.2% sequentially.
Historical Growth Trajectory
EVOK's historical revenue data shows a 3-year CAGR of +85.0%. Evoke Pharma, Inc.'s highest annual revenue of $10.2 million was recorded in 2024, an all-time high.
Revenue by Segment
EVOK's revenue is primarily driven by Pharmaceutical Products (100%). With over half of revenue concentrated in Pharmaceutical Products, the company has a focused business model while developing other growth vectors.
Peer Comparison
Compared to Healthcare sector peers — including PRPO (+23.6% YoY), AYTU (-18.2% YoY), and ANIP (+37.0% YoY) — EVOK has outperformed the peer group in revenue growth. Compare EVOK vs PRPO →
EVOK Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| EVOKCurrent | $14M | +61.4% | - | -50.8% | |
 PRPO | $16M | +23.6% | +38.6% | -26.4% | |
 AYTU | $66M | -18.2% | +19.2% | -11.8% | |
 ANIP | $883M | +37.0% | +33.5% | 9.2% |
EVOK Historical Revenue Data (2011–2024)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | $10.2M | +97.8% | $9.9M | 96.5% | $-5,204,137 | -50.8% |
| 2023 | $5.2M | +106.5% | $5.0M | 96.1% | $-7,430,891 | -143.4% |
| 2022 | $2.5M | +55.0% | $2.1M | 85.2% | $-7,786,137 | -310.4% |
| 2021 | $1.6M | +6929.0% | $1.3M | 79.7% | $-8,151,647 | -503.8% |
| 2020 | $23K | - | $-63,692 | -276.7% | $-13,047,349 | -56678.3% |
| 2019 | $0 | - | $0 | - | $-7,154,453 | - |
| 2018 | $0 | - | $0 | - | $-8,014,685 | - |
| 2017 | $0 | - | $0 | - | $-11,230,682 | - |
| 2016 | $0 | - | $0 | - | $-10,544,425 | - |
| 2015 | $0 | - | $0 | - | $-11,818,303 | - |
| 2014 | $0 | - | $0 | - | $-13,150,034 | - |
| 2013 | $0 | - | $0 | - | $-2,601,828 | - |
| 2012 | $0 | - | $0 | - | $-2,002,426 | - |
| 2011 | $0 | - | $0 | - | $-2,414,568 | - |
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
15+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
EVOK — Frequently Asked Questions
Quick answers to the most common questions about buying EVOK stock.
Is EVOK's revenue growth accelerating or slowing?
EVOK revenue growth is accelerating. TTM revenue reached $14M, up +61.4% year-over-year — ahead of the 5-year CAGR of N/A. This indicates the business is expanding faster than its historical baseline.
What is EVOK's revenue history from 2011 to 2026?
Evoke Pharma, Inc. (EVOK) revenue history spans 2011 to 2026. TTM revenue as of 2026 is $14M, growing at +61.4% YoY. The 5-year CAGR is N/A. Complete annual and quarterly revenue figures are available on this page, including gross profit, operating income, and margin trends.
What is EVOK's long-term revenue growth rate (CAGR)?
Evoke Pharma, Inc.'s 5-year revenue CAGR of N/A reflects the sustained nature of its business expansion. As of 2026, the current YoY growth rate of +61.4% is above this long-term average. CAGR is the most reliable measure of sustained revenue momentum for EVOK.
Why does EVOK's quarterly revenue fluctuate?
EVOK quarterly revenue can fluctuate significantly between periods. A quarter-over-quarter (QoQ) change does not always indicate a trend; comparing the same quarter year-over-year (YoY) is a more reliable signal for underlying growth. Evoke Pharma, Inc.'s revenue data from 2011 to 2026 shows full historical quarterly detail on this page.
How is EVOK's revenue distributed by segment?
EVOK reports revenue broken down by product line and geographic region. The segment breakdown on this page shows which business units contribute the most to total revenue as of the latest fiscal year. Concentration in a single segment above 50% indicates category dependence, while a diversified mix signals more resilient revenue streams.
How does EVOK's revenue compare to industry peers?
Evoke Pharma, Inc. (EVOK) with TTM revenue of $14M and +61.4% YoY growth can be benchmarked against sector peers using the comparison table on this page. Revenue growth relative to peers indicates market share gains or losses. The peer section shows TTM revenue, YoY growth, and operating margin for direct comparisons.